Location: Switzerland
Total raised: $37.59M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.08.2025 | - | $37.59M | - |
Mentions in press and media 6
| Date | Title | Description |
| 13.08.2025 | Mabylon Secures €31.8M for Allergy Antibody Breakthrough | Swiss biotech innovator Mabylon secured €31.8 million in crucial funding. This capital boost propels its human-derived antibody platform forward. The primary focus is advancing MY006, a tri-specific antibody for severe peanut allergy, into ... |
| 12.08.2025 | Swiss BioTech scale-up Mabylon raises €31.8 million to advance peanut allergy lead programme to clinical proof-of-concept | Zurich-based Mabylon, an innovator in the high-throughput discovery, characterisation, and development of human-derived antibodies, today announced that it has raised a total of €31.8 million to develop its clinical-stage lead candidate MY0... |
| 12.08.2025 | Mabylon raises CHF 30 million to fight allergies with human-derived antibodies | The funding combines a capital increase and a convertible loan of CHF 15 million, respectively. The funds are provided by Mabylon’s existing private investors, with the major investment coming from former management and board members of Ro... |
| 30.09.2024 | Financial support sets Mabylon on track to advance allergy treatments | Allergies, driven by a malfunctioning immune system, are increasingly prevalent and pose significant social and economic challenges, with severe cases like peanut allergy potentially leading to life-threatening anaphylaxis. Since its found... |
| 04.09.2023 | Global leaders accelerate mobility, security and therapeutics solutions | |
| - | Mabylon AG | “: Home” |